Arylpropanolamines: Selective β3 agonists arising from strategies to mitigate phase I metabolic transformations

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 15, 2007, Pages 4290-4296

  Washburn, W N ^a   Harper, T W ^a   Wu, G ^a   Godfrey, J D ^a   McCann, P ^a   Girotra, R ^a   Shao, C ^a   Zhang, H ^a   Gavai, A ^a   Mikkilineni, A ^a   Dejneka, T ^a   Ahmed, S ^a   Caringal, Y ^a   Hangeland, J ^a   Zhang, M ^a   Cheng, P T W ^a   Russell, A D ^a   Skwish, S ^a   Slusarchyk, D A ^a   Allen, G T ^a   Frohlich, B H ^a   Abboa Offei, B E ^a   Cap, M ^a   Waldron, T L ^a   George, R J ^a   Tesfamariam, B ^a   Dickinson, K E ^a   Seymour, A A ^a   Sher, P M ^a   more..

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

3 Agonists; Arylpropanolamine; Drug metabolism; Metabolic oxidative N dealkylation

Indexed keywords

4 HYDROXY 3 METHYLSULFONANILIDOETHANOLAMINE DERIVATIVE; ARYPROPANOLAMINE DERIVATIVE; BETA 3 AGONIST; BETA ADRENERGIC RECEPTOR; N 4 HYDROXY 3 METHYLSULFONANILIDOETHANOLAMINE DERIVATIVE; PROPANOLAMINE DERIVATIVE; UNCLASSIFIED DRUG; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT;

ARTICLE; CHEMICAL STRUCTURE; DEALKYLATION; STEREOCHEMISTRY; ALKYLATION; CHEMISTRY; DRUG POTENTIATION; OXIDATION REDUCTION REACTION; STRUCTURE ACTIVITY RELATION;

ADRENERGIC BETA-AGONISTS; ALKYLATION; OXIDATION-REDUCTION; PROPANOLAMINES; RECEPTORS, ADRENERGIC, BETA-3; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34347402001     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.05.030     Document Type: Article

References (32)

1. Washburn W.N., Sher P.M., Poss K., Girotra R.N., McCann P.J., Gavai A.V., Mikkilineni A.B., Mathur A., Cheng P., Dejneka T.C., Sun C.Q., Wang T.C., Harper T.W., Russell A.D., Slusarchyk D.A., Skwish S., Allen G.T., Hillyer D.E., Frohlich B.H., Abboa-Offei B.E., Cap M., Waldron T.L., George R.J., Tesfamariam B., Ciosek C.P., Young D.A., Dickinson K.E., Seymour A.A., Arbeeny C.M., and Gregg R.E. Bioorg. Med. Chem. Lett. 11 (2001) 3035
2. Gavai A.V., Sher P.M., Mikkilineni A.B., Poss K.M., McCann P.J., Girotra R.N., Fisher L.G., Wu G., Bednarz M.S., Mathur A., Wang T.C., Sun C.Q., Slusarchyk D.A., Young D.A., Dickinson K.E., Seymour A.A., Arbeeny C.M., and Washburn W.N. Bioorg. Med. Chem. Lett. 11 (2001) 3041
3. Washburn W.N., Sun C.Q., Bisacchi G., Wu G., Cheng P., Sher P.M., Ryono D., Gavai A.V., Poss K., Girotra R.N., McCann P.J., Mikkilineni A.B., Dejneka T.C., Wang T.C., Merchant Z., Morella M., Arbeeny C.M., Harper T.W., Slusarchyk D.A., Skwish S., Russell A.D., Allen G.T., Tesfamariam B., Frohlich B.H., Abboa-Offei B.E., Cap M., Waldron T.L., George R.J., Young D., Dickinson K.E., and Seymour A.A. Bioorg. Med. Chem. Lett. 14 (2004) 3525
4. Himms-Hagen J., and Ricquier D. In: Bray G.A., Bouchard C., and James W.P.T. (Eds). Handbook of Obesity (1998), Marcel Dekher, New York 415
5. Larsen A.A., Gould W.A., Roth H.R., Comer W.T., and Uloth R.H. J. Med. Chem. 10 (1967) 462
6. Guengerich F.P., Yun C.H., and Macdonald T.L. J. Biol. Chem 271 (1996) 27321
7. Guengerich F.P. Chem. Res. Toxicol. 14 (2001) 611
8. Hu B., Ellingboe J., Han S., Largis E., Mulvey R., Oliphant A., Sum F.-W., and Tillet J. J. Med. Chem. 44 (2001) 1456
9. 100 for mice was 57 μg/kg of 2 administered iv; iv doses of 0.5-5.7 μg/kg produced progressively more pronounced piloerection; 0.05 μg/kg was a no effect dose. This dose dependent response suggested that piloerection following iv administration of 10 mg/kg of 1 during the murine safety screen was indicative of 0.01-0.1% of the dose being converted to 2. A few compounds, such as 1f, were lethal at 10 mg/kg but not at 1 mg/kg implying that metabolic conversion to 2 was ∼0.1-1%.
10. Typically, a 100 μM solution of compounds of structure 1 was incubated for 3 h in pH 7.4 phosphate buffer (0.1 M) containing African green monkey hepatic microsomes (3 mg/mL protein) and 3 mM NADPH whereupon the protein was precipitated by addition of 2 volumes MeCN prior to determination of the conversion to 2 by LC/MS. Since control studies entailing incubation of compounds of structure 1 as described above in the absence of NADPH generated minuscule amounts of 2, solvolytic release of 2 due to chemical instability of 1 after protonation was of minimal importance.
11. Subsequently during clinical studies with BMS-196085 (1c), BMS-194449 (1b), and BMS-201620 (1j) dose dependent incidences of sweaty palms, flushing, and piloerection, all classic manifestations of an α adrenergic agonist, as well as detection of trace levels of 2 validated these concerns regarding metabolic liberation of 2.
12. Kirk K.L., Cantacuzene D., and Creveling C.R. Biomed. Aspects Fluorine Chem. (1982) 75
13. Brasili L., Cantalamessa F., Picchio M.T., and Quaglia W. Eur. J. Pharm. 144 (1987) 141
14. Hieble J.P., Hehr A., Li Y., and Ruffolo R.R. Proc. Western Pharmacol. Soc. 41 (1998) 225
15. 15 IA is given as a percentage of the maximal stimulation with isoproterenol.
16. 3 adrenergic receptor reported by. Emorine L.T., Marullo S., Briend-Sutren M.M., Patey G., Tate K., Delavier-Klutchko C., and Strosberg A.D. Science 245 (1989) 1118
17. Sher P.M., Fisher L.G., Skwish S., Michel I.M., Seiler S.M., Washburn W.N., and Dickinson K.E. J. Med. Chem. Res. 7 (1997) 109
18. Spectral data were fully consistent with structures.
19. Beeley L.J., Berge J.M., Chapman H., Dean D.K., Kelly J., Lowden K., Kotecha N.R., Morgan H.K.A., Rami H.K., Thompson M., Vong A.K.K., and Ward R.W. Bioorg. Med. Chem. Lett. 7 (1997) 219
20. 1/2 was ∼40 min to presumably generate quinones.
21. Larson, A. A.; Gould, W. A. US Patent 1,171,477.
22. Wu G., Cai Z.W., Bednarz M.S., Kocy O., Gavai A.V., Godfrey J.D., Washburn W.N., and Sher P.M. J. Comb. Chem. 7 (2005) 99
23. 22.
24. Fuhrer W., Ostermayer F., Zimmermann M., Meier M., and Müller H. J. Med. Chem. 27 (1984) 831
25. Lövgren K., Hedberg H., and Nilsson J.L.G. J. Med. Chem. 24 (1981) 451
26. Alderová E., Trčka V., Šmejkal V., and Protiva M. Collect. Czech. Chem. Commun. 34 (1969) 479
27. WO 2000/012462.
28. WO 1999/051564.
29. Absolute stereochemistry of 15f assigned by X-ray crystallography.
30. 2 IA was determined by measuring relaxation of guinea pig trachea rings submaximally contracted with carbacol relative to that induced by isoproterenol.
31. Tesfamariam B., and Allen G.T. Br. J. Pharmacol. 112 (1994) 55
32. Lipworth B.J., McFarlane L.C., Coutie W.J., and McDevitt D. Eur. J. Clin. Pharmacol. 37 (1989) 297